Adverum Biotechnologies Inc. has notified its stockholders to tender their shares as part of a pending acquisition by Eli Lilly and Company. The company emphasized that the $3.56 per share all-cash offer delivers immediate liquidity and certainty of value to stockholders, highlighting that without the Lilly transaction, Adverum would lack sufficient liquidity to continue operations or repay its debt, likely resulting in bankruptcy. The Board of Directors considers the Lilly offer the best available alternative for stockholders given the company's financial situation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adverum Biotechnologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594264-en) on December 01, 2025, and is solely responsible for the information contained therein.